Skip to main content
Biosimilars
Incidence of Hypertension and Proteinuria in Bevacizumab- and Bevacizumab Biosimilar-Treated Cohorts
Read More
Biosimilars
Cost-Efficiency Analysis of Switching from Reference Pegfilgrastim to Pegfilgrastim-jmdb
Read More
Biosimilars
Real-World Data Showed Comparable pCR Rates with Neoadjuvant Chemotherapy plus Trastuzumab-dkst versus Trastuzumab
Read More
Biosimilars
Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for the Treatment of High-Risk, HER2-Positive Early Breast Cancer
Read More
Biosimilars
Real-World Overall Response Rate and Other Outcomes Related to Originator and Biosimilar Rituximab in Patients with CLL or NHL in the United Kingdom
Read More
Lung Cancer
Severe Adverse Events from Immune Checkpoint Inhibitor Therapy a Rare Concerning Side Effect
Read More
Lung Cancer
KRASᴳ¹²ᶜ Mutation–Positive Advanced NSCLC
Read More
Lung Cancer
CodeBreaK 100 Trial Results Demonstrate Sotorasib Conveys Clinical Benefit Across NSCLC Patient Subgroups
Read More
Lung Cancer
NSAID Use with Immune Checkpoint Inhibitors Associated with Longer Overall Survival in NSCLC
Read More
Lung Cancer
The Effect of Various KRAS Mutations on NSCLC Susceptibility
Read More
Page 74 of 199
Results 731 - 740 of 1986